[177Lu]pertuzumab: Experimental therapy of HER-2-expressing xenografts

Mikael Persson, Lars Gedda, Hans Lundqvist, Vladimir Tolmachev, Hans Nordgren, Per Uno Malmström, Jörgen Carlsson

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)

Abstract

Pertuzumab (Omnitarg) is a novel antibody against HER-2, domain II. HER-2 is a tyrosine kinase receptor that is overexpressed in several carcinomas, especially breast cancer. Pertuzumab, labeled with the low-energy β emitter 177Lu, might be a candidate for targeted radiotherapy of disseminated HER-2-positive micrometastases. The radiolabeled antibody [ 177Lu]pertuzumab showed favorable targeting properties in BALB/c (nu/nu) mice with HER-2-overexpressing xenografts. The absorbed dose in tumors was more than five times higher than the absorbed dose in blood and more than seven times the absorbed dose in any other normal organ. Experimental therapy showed that [177Lu]pertuzumab delayed tumor progression compared with controls (no treatment, P < 0.0001; nonlabeled pertuzumab antibody, P < 0.0001; and 177Lu-labeled irrelevant antibody, P < 0.01). No adverse side effects of the treatment could be detected. Thus, the experimental results support the planning of clinical studies applying [177Lu] pertuzumab for therapy.

Original languageEnglish
Pages (from-to)326-331
Number of pages6
JournalCancer Research
Volume67
Issue number1
DOIs
Publication statusPublished - 1 Jan 2007
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '[<sup>177</sup>Lu]pertuzumab: Experimental therapy of HER-2-expressing xenografts'. Together they form a unique fingerprint.

Cite this